VPC
PTGX icon

Vestal Point Capital’s Protagonist Therapeutics PTGX Stock Holding History

Vestal Point Capital’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-326,159
Closed -$34.4M – 87
2026
Q1 		$34.4M Buy
+326,159
New +$28.9M 0.96% 37

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Vestal Point Capital's PTGX Position: Q2 2026 in Review

Vestal Point Capital sold out of Protagonist Therapeutics (PTGX) in Q2 2026, closing a stake of 326,159 shares — an estimated $34.4M sold.

Vestal Point Capital first reported a position in PTGX in Q1 2026 and held it in 1 quarter. The position peaked at $34.4M in Q1 2026. 343 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • Vestal Point Capital reported no remaining Protagonist Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Vestal Point Capital sold 326,159 Protagonist Therapeutics shares in Q2 2026, an estimated $34.4M.
  • Vestal Point Capital first reported a position in Protagonist Therapeutics in Q1 2026 and held it in 1 quarter.
  • Vestal Point Capital's Protagonist Therapeutics position peaked at $34.4M in Q1 2026.
  • 343 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Vestal Point Capital's 13F filing for Q2 2026, filed 14 Aug 2026.